Past Press Releases - Evolva SA

December 14, 2009
Evolva raises additional CHF 21 million
Listing on SIX Swiss Exchange under name Evolva Holding SA More

October 29, 2009
Evolva appoints Jessica Mann as Chief Medical Officer
Evolva SA, a Swiss headquartered international biotech company has expanded its management team by appointing Jessica Mann as Chief Medical Officer. More

August 27, 2009
Evolva appoints Jutta Heim as chief technology officer
Evolva SA, a Swiss headquartered international biotech company has expanded its Management team by appointing Jutta Heim as Chief Technology Officer. More

July 16, 2009
Evolva successfully completes Phase I single ascending dose trial on EV-077
Evolva successfully completes Phase I single ascending dose trial on EV-077 for renal and cardiovascular indications More

March 18, 2009
Evolva starts Phase I Clinical Trials on EV-077
Evolva SA, an international biotech company focused on the discovery and development of drugs based on its genetic chemistry platform, today announced it has started Phase I Clinical Trials with its drug candidate EV-077-3201-2TBS. More

November 4, 2008
Evolva receives funding from the Global Cardiovascular Innovation Center
Evolva today announced that it has received a $288,000 award from the Cleveland Clinic led Global Cardiovascular Innovation Center (GCIC). More

November 8, 2006
Evolva announces $26.7 million award from the United States Defense Threat Reduction Agency
Evolva Biotech, a biotech company focused on the discovery and development of drugs based on genetic chemistry approaches, has received a $26.7 million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of therapeutics that improve the ability of humans to resist diverse pathogens, in particular potential biowarfare or bioterrorism agents. More

September 2, 2005
Evolva acquires pharmaceutical business of Poalis
Evolva has acquired the pharmaceutical business and associated assets of Poalis. Evolva will integrate certain Poalis employees into Evolva’s existing Danish operations, and take over the running of the Poalis facility at KVL in Copenhagen. More

July 1, 2005
Evolva & AnalytiCon enter Nuclear Receptor Alliance
Evolva Biotech and AnalytiCon Discovery GmbH have entered into a strategic alliance to jointly apply their respective technologies to the generation and optimization of novel nuclear receptor agonists and related compounds. More